Miyahara, Koji <br/><br/>
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.  [electronic resource] 

 -  Journal of gastroenterology and hepatology  Nov 2011 
 - 1604-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1440-1746 
<br/><br/><label>Standard No.: </label>10.1111/j.1440-1746.2011.06887.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenic Proteins--blood<br/>Antineoplastic Agents--adverse effects<br/>Benzenesulfonates--adverse effects<br/>Biomarkers, Tumor--blood<br/>Carcinoma, Hepatocellular--blood<br/>Cytokines--blood<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Japan<br/>Kaplan-Meier Estimate<br/>Liver Neoplasms--blood<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyridines--adverse effects<br/>Risk Assessment<br/>Risk Factors<br/>Sorafenib<br/>Survival Rate<br/>Time Factors<br/>Treatment Outcome<br/>Up-Regulation